COMPARISON OF NONSTEROIDAL ANTI-INFLAMMATORY OF COX-1 AND COX-2 REGARDING SIDE EFFECTS IN THE ASTROINTESTINAL TRACT
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat symptoms caused by rheumatoid arthritis due to their ability to inhibit prostaglandin synthesis by inhibiting cyclooxygenase (COX). The side effects of NSAIDs are also associated with inhibiting prostaglandin production. Consequently, their application is problematic. NSAID selective COX-2 inhibitors give minor gastrointestinal complications. Our study aims to compare nonsteroidal anti-inflammatory inhibitors of COX-1 and COX-2 regarding side effects in the gastrointestinal tract of patients with rheumatoid arthritis.
Keywords: Nonsteroidal anti-infammatory drugs, rheumatoid arthtritis, COX-2, gastrointestinal tract, PPIs.
References
Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. D.J. Magee, S. Jhanji, G. Poulogiannis, P. Farquhar-Smith, M.R.D. BrownBr J Anaesth. 2019 Aug; 123(2): e412–e423.
Marsico, Fabio; Paolillo, Stefania; Filardi, Pasquale P. NSAIDs and cardiovascular risk, Journal of Cardiovascular Medicine: January 2017 - Volume 18-Issue-p e40-e43 doi: 10.2459/JCM.0000000000000443.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23; 231(25):232-5.
Adelizzi RA. COX-1 and COX-2 in health and disease. J Am Osteopath Assoc. 1999 Nov; 99(11 Suppl):S7-12.
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998 Sep; 12(12):1063-73.
Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019 Jan 1; 170(1): ITC1-ITC16. Doi: 10.7326/AITC201901010. PMID: 30596879.
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb;4:18001.
Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007 Mar; 5((1)):19–34.
Fidahic M, JelicicKadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD012095. doi: 10.1002/14651858.CD012095.pub2. PMID: 28597983; PMCID: PMC6481589.
Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. Drugs Aging. 2019;36(Suppl 1):15-24. doi:10.1007/s40266-019-00660-1.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343:1520–8.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature. 1971;231:232-5.
Whittle BJ. Arachidonic acid metabolites and the gastro-intestinal toxicity of anti-inflammatory agents. Prostaglandins. 1981;21 Suppl:113-8.
Vane JR. Towards a better aspirin. Nature. 1994;367:215-6.
Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and gastrointestinal damage induced by indomethacin in the rat. Gastroenterology. 1981;80:94-8.
Peskar BM. On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs.BiochemBiophysacta. 1977;487:307-14.
Strub KM, Muller RK. Relation between ulcerogenic activity of various NSAID and their potency as inhibitors of prostaglandin synthesis in vivo.Agents Actions. 1979;4 Supplement:245-54.
Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute NSAID-associated gastroduodenal mucosal damage by misoprostol.Br J Rheumatol. 1993;32:990-5.
Rostom A, Muir K, Dubé C J, et al. Ga-strointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. ClinGastroenterolHepatol. 2007;5:818-28.
Whittle BJR. Protective mechanisms of the gastric mucosa. In Gustsavsson S, Kumar D, Graham DY, (eds.) The Stomach. Churchill Livingstone, Edinburgh. 1992:81-101
Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med. 2001; 110(1A):12S–3S. Epub 2001/02/13.
Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. Drugs Aging. 2019; 36(Suppl 1):15-24. doi:10.1007/s40266-019-00660-1.
Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med PrincPract. 2018;27(6):501-507. doi:10.1159/000493390
Downloads
Published
How to Cite
Issue
Section
License
Declaration/Copyright transfer:
1. In consideration of the undertaking set out in paragraph 2, and upon acceptance by ANGLISTICUM for publication of the manuscript in the Journal, I/We hereby assign and transfer publication rights to ANGLISTICUM, whereas I/We retain the copyright for the manuscript. This assignment provides ANGLISTICUM the sole right and responsibility to publish the manuscript in its printed and online version, and/or in other media formats.
2. In consideration of this assignment, ANGLISTICUM hereby undertakes to prepare and publish the manuscript in the Journal, subject only to its right to refuse publication if there is a breach of the Author’s warranty in paragraph 4 or if there are other reasonable grounds.
3. Editors and the editorial board of ANGLISTICUM are empowered to make such editorial changes as may be necessary to make the Manuscript suitable for publication.
4. I/We hereby acknowledge that: (a) The manuscript submitted is an original work and that I/We participated in the work substantively and thus I/We hereby are prepared to take public responsibility for the work; (b) I/We hereby have seen and approved the manuscript as submitted and that the manuscript has not either been published, submitted or considered for publication elsewhere; (c) The text, illustration, and any other materials included in the manuscript do not infringe upon any existing copyright or other rights of anyone.
5. I/We hereby indemnify ANGLISTICUM and the respective Editors of the Journal as mentioned in paragraph 3, and hold them harmless from any loss, expense or damage occasioned by a claim or suit by a third party for copyright infringement, or any suit arising out of any breach of the foregoing warranties as a result of publication of the manuscript.